Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zarnestra (tipifarnib) + Doxorubicin + Cyclophosphamide in Advanced Breast Cancer
NCT00049114Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2003
- Primary completion
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tipifarnib in breast cancer, sponsored by National Cancer Institute. Primary endpoint: Pathological complete response in the breast at 8 weeks. Started Feb 2003; status: completed.
02
Drugs
tipifarnib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00049114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00049114.